MSCopilot®: New clinical results confirm central role of digital biomarkers in the monitoring of patients with multiple sclerosis

November 10, 2021

A recent publication in "Multiple Sclerosis and Related Disorders" confirms the medical relevance of MSCopilot®, the first medical device for the self-assessment of multiple sclerosis in real-life. These new results strengthen the place of MSCopilot® in the care pathway of the 110,000 patients with multiple sclerosis in France (PwMS).

Share

MSCopilot®: New clinical results confirm central role of digital biomarkers in the monitoring of patients with multiple sclerosis Our news
en_USEnglish